DBV Technologies Stock Rebounds Nearly 2% at €2.75 Support
The French biotech continues its technical rebound in a Parisian market buoyed by a significant easing of the VIX. The stock is attempting to build a base after several weeks of sliding, but remains distant from its medium-term benchmarks.
A Modest Rebound Insufficient to Offset a 17% Monthly Decline
DBV Technologies stock is up 1.91% at €2.88 in early afternoon trading, with the SBF 120 up by 1.79%. The stock extends the recovery movement observed the previous day at its €2.75 support, after a pronounced slide. Over a month, the decline still reaches 17.44%, and over three months 25.92%. However, the annual performance remains high at +88.1%, a legacy of the rally that accompanied clinical developments around the Viaskin Peanut patch.
The day's rebound barely softens the underlying bearish dynamics. The price still operates below its three moving averages: 7.46% below the MM20 (€3.11), 14.35% below the MM50 (€3.36), and 4.07% below the MM200 (€3.00). The RSI at 33 remains close to the oversold zone, consistent with the selling pressure of recent weeks. The MACD remains in negative territory, with the histogram at -0.04 indicating no clear reversal.
Positive Data from VITESSE Study Supports Technical Recovery
The clinical context sheds light on this recovery movement. A few days ago, DBV Technologies unveiled new positive data from its phase 3 VITESSE study, which evaluates the epicutaneous immunotherapy patch in children allergic to peanuts. Concurrently, the company presented the protocol for its phase 2 THRIVE study, extended to infants aged 6 to 12 months. Both studies will be detailed at the 2026 congress of the European Academy of Allergology. CEO Daniel Tassé also spoke on June 9 at the Goldman Sachs Global Healthcare conference in Miami, during a fireside chat focused on the group's strategy.
The €2.75 support, tested at the beginning of the week, remains the short-term technical reference threshold. The next resistance is at €3.63, a level that would correspond to a return above the short moving averages.
